Notably, in the subgroup with tyrosine kinase inhibitor (TKI) -resistant epidermal growth factor receptor (EGFR) -mutant NSCLC, an ORR of 60% and a median PFS of 11.1 months were recorded. Here, EGFR is linked to non-small cell lung carcinoma.